Cooling the fire within: Inhaled corticosteroids and cardiovascular mortality in COPD

Chest

Volumn 130, Issue 3, 2006, Pages 629-631

  Sin, Don D ^a,b,c   Man, S F Paul ^a,b,c  

^a St Paul's Hospital ^*

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; EDITORIAL; HUMAN; INFLAMMATION; LUNG FUNCTION; MORTALITY; PRIORITY JOURNAL;

EID: 33748875091     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.3.629     Document Type: Editorial

References (17)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projects. Eur Respir J 2006; 27:397-412
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available at: www.goldcopd.com. Accessed July 6, 2006
3. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease. JAMA 2003; 290:2301-2312
4. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364:709-721
5. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514-1519
6. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128:1995-2004
7. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55:114-120
8. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers, and non-smokers. Thorax 2006; 61:23-28
9. Can WQ, Man SFP, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5:3
10. Ozol D, Aysan T, Solak ZA, et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005; 99:1494-1500
11. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760-765
12. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333-339
13. Macie C, Wooldrage K, Manfreda J, et al. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130:640-646
14. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60:992-997
15. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771-777
16. Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myoeardial infarction in COPD. Eur Respir J 2005; 25:634-639
17. Löfdahl CG, Postma D, Pride N, et al. Does inhaled budesonide protect against cardio-ischemic events in mild-moderate COPD: a post-hoc evaluation of the EUROSCOP study [abstract]. Eur Respir J Suppl 2005; 26:2333